Mostrando 10 resultados de: 27
Filtros aplicados
Publisher
Journal of Nanobiotechnology(4)
Pharmaceutics(3)
Nanomaterials(2)
AAPS Advances in the Pharmaceutical Sciences Series(1)
Applied Sciences (Switzerland)(1)
Área temáticas
Farmacología y terapéutica(20)
Enfermedades(18)
Medicina y salud(10)
Fisiología humana(7)
Ginecología, obstetricia, pediatría, geriatría(3)
Área de conocimiento
Farmacología(10)
Nanopartícula(7)
Biotecnología(6)
Neurología(6)
Ciencia de materiales(4)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(27)
ODS 10: Reducción de las desigualdades(20)
ODS 12: Producción y consumo responsables(5)
ODS 2: Hambre cero(2)
Origen
scopus(27)
A metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusA novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusBiodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
ReviewAbstract: Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized byPalabras claves:Epilepsy, lipid nanoparticles, Nanomedicine, nanotechnology, neurodegenerative diseases, Polymeric nanoparticlesAutores:Antoni Camins, Bonilla L., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusArticle dexibuprofen biodegradable nanoparticles: One step closer towards a better ocular interaction study
ArticleAbstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect variousPalabras claves:Dexibuprofen, Drug delivery system, Nanoparticles, PLGAAutores:Alsafi Z., Antoni Camins, Calpena A.C., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Muñoz M., Ortiz A., Prat J., Pujol M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusDevelopment and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment
ArticleAbstract: Riluzole-loaded PLGA nanoparticles (RLZ-NPs) were developed to improve the biopharmaceutical profilePalabras claves:Gellan gum, glaucoma, In situ gelling gel, PLGA nanoparticles, riluzoleAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García-Torra V., Halbaut L., Luisa García M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusExtracellular vesicles, the emerging mirrors of brain physiopathology
ArticleAbstract: Extracellular vesicles are secreted by a wide variety of cells, and their primary functions includePalabras claves:Alzheimer’s disease, exosomes, Extracellular vesicles, Glioblastoma, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, Parkinson’s DiseaseAutores:Antoni Camins, Bernuz M., Boada M., Cano A., de Antonio E.E., Ettcheto M., Martí M., Pividori M.I., Puerta R., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopus